WO2004058988A3 - Binding agents which inhibit myostatin - Google Patents

Binding agents which inhibit myostatin Download PDF

Info

Publication number
WO2004058988A3
WO2004058988A3 PCT/US2003/040781 US0340781W WO2004058988A3 WO 2004058988 A3 WO2004058988 A3 WO 2004058988A3 US 0340781 W US0340781 W US 0340781W WO 2004058988 A3 WO2004058988 A3 WO 2004058988A3
Authority
WO
WIPO (PCT)
Prior art keywords
binding agents
binding
present invention
myostatin
muscle
Prior art date
Application number
PCT/US2003/040781
Other languages
French (fr)
Other versions
WO2004058988A2 (en
Inventor
Hq Han
Hosung Min
Thomas Charles Boone
Original Assignee
Amgen Inc
Hq Han
Hosung Min
Thomas Charles Boone
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US43592302P priority Critical
Priority to US60/435,923 priority
Application filed by Amgen Inc, Hq Han, Hosung Min, Thomas Charles Boone filed Critical Amgen Inc
Publication of WO2004058988A2 publication Critical patent/WO2004058988A2/en
Publication of WO2004058988A3 publication Critical patent/WO2004058988A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/35Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/14011Baculoviridae
    • C12N2710/14111Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors

Abstract

The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therepeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and other metabolic disorders including diabetes and obesity.
PCT/US2003/040781 2002-12-20 2003-12-19 Binding agents which inhibit myostatin WO2004058988A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US43592302P true 2002-12-20 2002-12-20
US60/435,923 2002-12-20

Applications Claiming Priority (29)

Application Number Priority Date Filing Date Title
KR1020137033417A KR20140004805A (en) 2002-12-20 2003-12-19 Binding agents which inhibit myostatin
MEP-575/08A MEP57508A (en) 2002-12-20 2003-12-19 Binding agents which inhibit myostatin
KR1020157024227A KR20150107899A (en) 2002-12-20 2003-12-19 Binding agents which inhibit myostatin
CN2003801099052A CN101287484B (en) 2002-12-20 2003-12-19 Binding agents which inhibit myostatin
KR1020137007048A KR20130036378A (en) 2002-12-20 2003-12-19 Binding agents which inhibit myostatin
EP03814258A EP1581649B1 (en) 2002-12-20 2003-12-19 Binding agents which inhibit myostatin
AT03814258T AT496938T (en) 2002-12-20 2003-12-19 Myostatin-inhibiting binding materials
NZ541253A NZ541253A (en) 2002-12-20 2003-12-19 Peptide binding agents which inhibit myostatin
MXPA05006521A MXPA05006521A (en) 2002-12-20 2003-12-19 Binding agents which inhibit myostatin.
KR1020157000046A KR20150013350A (en) 2002-12-20 2003-12-19 Binding agents which inhibit myostatin
CA2510893A CA2510893C (en) 2002-12-20 2003-12-19 Binding agents which inhibit myostatin
DK03814258.4T DK1581649T3 (en) 2002-12-20 2003-12-19 Myostatininhiberende binders
DE60335915A DE60335915D1 (en) 2002-12-20 2003-12-19 Myostatin-inhibiting binding materials
JP2004563875A JP4959137B2 (en) 2002-12-20 2003-12-19 Binding agents that inhibit myostatin
YU20050530A RS52815B (en) 2002-12-20 2003-12-19 Binding agents which inhibit myostatin
KR1020127013452A KR20120060250A (en) 2002-12-20 2003-12-19 Binding agents which inhibit myostatin
AU2003301195A AU2003301195B2 (en) 2002-12-20 2003-12-19 Binding agents which inhibit myostatin
BR0317538-3A BR0317538A (en) 2002-12-20 2003-12-19 Agent linker polynucleotide sequence, expression vector, host cell, pharmaceutical composition, and methods of inhibiting myostatin activity in increasing lean muscle mass and lean muscle mass ratio for fat, treating a muscle wasting disease and a metabolic disorder associated with myostatin in an individual, to detect and measure myostatin in a sample, and to diagnose a disorder related to myostatin in an individual
KR1020057011611A KR101304718B1 (en) 2002-12-20 2003-12-19 Binding agents which inhibit myostatin
EA200501000A EA009056B1 (en) 2002-12-20 2003-12-19 Binding agents that inhibit myostatin
KR1020167010048A KR20160045936A (en) 2002-12-20 2003-12-19 Binding agents which inhibit myostatin
SI200331987T SI1581649T1 (en) 2002-12-20 2003-12-19 Binding agents which inhibit myostatin
IL169168A IL169168D0 (en) 2002-12-20 2005-06-15 Binding agents which inhibit myostatin
NO20053545A NO335982B1 (en) 2002-12-20 2005-07-19 Binding agents which inhibit myostatin, process for their preparation, pharmaceutical composition thereof and the use thereof for preparing a composition, method of detecting or diagnosing a myostatinrelatert disorder and methods of measuring myostatin in a sample.
HK06104082.5A HK1084419A1 (en) 2002-12-20 2006-04-03 Binding agents which inhibit myostatin
AU2010201389A AU2010201389A1 (en) 2002-12-20 2010-04-07 Binding agents which inhibit myostatin
IL205265A IL205265A (en) 2002-12-20 2010-04-22 Binding agent comprising at least one peptide capable of binding myostatin, a polynucleotide sequence encoding the binding agent, an expression vector comprising the polynucleotide, a host cell comprising the expression vector, a pharmaceutical composition comprising the binding agent and uses thereof, a method of detecting or measuring myostatin in a sample and a method of diagnosing a myostatin related disorder in a subject
IL205266A IL205266D0 (en) 2002-12-20 2010-04-22 Binding agents which inhibit myostatin
NO20141479A NO20141479L (en) 2002-12-20 2014-12-05 Binding agents which inhibit myostatin

Publications (2)

Publication Number Publication Date
WO2004058988A2 WO2004058988A2 (en) 2004-07-15
WO2004058988A3 true WO2004058988A3 (en) 2007-11-15

Family

ID=32682298

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/040781 WO2004058988A2 (en) 2002-12-20 2003-12-19 Binding agents which inhibit myostatin

Country Status (28)

Country Link
US (7) US7511012B2 (en)
EP (2) EP1581649B1 (en)
JP (3) JP4959137B2 (en)
KR (9) KR20160045936A (en)
CN (2) CN102382172A (en)
AR (2) AR042545A1 (en)
AT (1) AT496938T (en)
AU (2) AU2003301195B2 (en)
BR (1) BR0317538A (en)
CA (2) CA2510893C (en)
CY (1) CY1111388T1 (en)
DE (1) DE60335915D1 (en)
DK (1) DK1581649T3 (en)
EA (1) EA009056B1 (en)
ES (1) ES2359562T3 (en)
HK (1) HK1084419A1 (en)
IL (3) IL169168D0 (en)
ME (1) MEP57508A (en)
MX (1) MXPA05006521A (en)
NO (2) NO335982B1 (en)
NZ (1) NZ541253A (en)
PL (1) PL383616A1 (en)
PT (1) PT1581649E (en)
RS (1) RS52815B (en)
SI (1) SI1581649T1 (en)
TW (1) TWI328456B (en)
WO (1) WO2004058988A2 (en)
ZA (1) ZA200505481B (en)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1250721C (en) 1998-10-23 2006-04-12 安姆根有限公司 Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US7572763B2 (en) * 2002-02-21 2009-08-11 Wyeth Follistatin domain containing proteins
CA2476887A1 (en) * 2002-02-21 2003-09-04 Wyeth Gasp1:a follistatin domain containing protein
US7193069B2 (en) * 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
BR0314270A (en) * 2002-09-16 2005-08-02 Univ Johns Hopkins myostatin activation with metalloprotease and modulation processes myostatin activity
US7261893B2 (en) * 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
AU2003301195B2 (en) 2002-12-20 2010-01-07 Amgen Inc. Binding agents which inhibit myostatin
CN1829532A (en) * 2003-06-02 2006-09-06 惠氏公司 Use of myostatin (GDF8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
AT540980T (en) 2003-11-13 2012-01-15 Hanmi Holdings Co Ltd Protein complex with immunoglobulin fragment and process for its manufacture
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
EP1699820A2 (en) 2003-12-31 2006-09-13 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine
US9045553B2 (en) 2004-05-27 2015-06-02 Acceleron Pharma, Inc. Cerberus/Coco derivatives and uses thereof
US7316998B2 (en) * 2004-05-27 2008-01-08 Acceleron Pharma Inc. Cerberus/Coco derivatives and uses thereof
CA2572765C (en) * 2004-07-08 2013-05-21 Amgen Inc. Compound having improved bioefficiency when administered in a multidose regimen
BRPI0516011A (en) * 2004-09-24 2008-08-19 Amgen Inc modified molecules fc
MX2007008132A (en) 2004-12-30 2007-07-20 Schering Plough Ltd Neutralizing epitope-based growth enhancing vaccine.
NZ538097A (en) * 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
BRPI0609439A2 (en) * 2005-03-23 2010-04-06 Wyeth Corp detecting an immune response modulating agents GDF-8
US20060240487A1 (en) * 2005-03-23 2006-10-26 Nowak John A Detection of GDF-8 modulating agents
JP2008543839A (en) 2005-06-14 2008-12-04 アムジェン インコーポレーテッドAmgen Inc. Self-buffering protein formulations
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2007044411A2 (en) 2005-10-06 2007-04-19 Eli Lilly And Company Anti-myostatin antibodies
KR101128548B1 (en) * 2005-10-12 2012-03-23 일라이 릴리 앤드 캄파니 Anti-myostatin antibodies
US20090163579A1 (en) * 2005-10-14 2009-06-25 Daniel Raederstorff Novel use of nutraceutical compositions
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
EP1968621A2 (en) * 2005-12-06 2008-09-17 Amgen Inc. Uses of myostatin antagonists
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
CA2661836A1 (en) 2006-09-05 2008-03-13 Eli Lilly And Company Anti-myostatin antibodies
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
US7833971B2 (en) * 2006-12-08 2010-11-16 Acceleron Pharma Inc. Uses of cerberus, coco and derivatives thereof
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
BR112014015003A2 (en) 2011-12-19 2017-06-13 Amgen Inc A pharmaceutical composition, method of treating a cancer and method for reducing the size of a tumor mass
TWI573802B (en) 2007-03-06 2017-03-11 Amgen Inc Variant activin receptor polypeptides and uses thereof
EP2738257A1 (en) 2007-05-22 2014-06-04 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
WO2009015345A1 (en) * 2007-07-25 2009-01-29 Amgen Inc. Pharmaceutical compositions comprising fc fusion proteins
RS55735B1 (en) 2007-08-03 2017-07-31 Summit (Oxford) Ltd Drug combinations for the treatment of duchenne muscular dystrophy
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
CA2698103A1 (en) * 2007-08-31 2009-03-05 Amgen Inc. Solid-state protein formulation
CA2701032A1 (en) 2007-09-27 2009-04-02 Amgen Inc. Pharmaceutical formulations
EP3381445A3 (en) 2007-11-15 2019-01-16 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
KR101760758B1 (en) 2008-05-14 2017-07-24 애그리컬쳐 빅토리아 서비스 피티와이 엘티디 Use of angiogenin or angiogenin agonists for treating diseases and disorders
CA2743850C (en) 2008-11-26 2018-04-17 Amgen Inc. Variants of activin iib receptor polypeptides and uses thereof
KR101741859B1 (en) 2009-06-22 2017-06-15 암젠 인크 Refolding proteins using a chemically controlled redox state
JP2012531428A (en) * 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド Capture purification process of proteins expressed in a system of non-mammalian
US8945511B2 (en) * 2009-06-25 2015-02-03 Paul Weinberger Sensitive methods for detecting the presence of cancer associated with the over-expression of galectin-3 using biomarkers derived from galectin-3
US9662271B2 (en) 2009-10-23 2017-05-30 Amgen Inc. Vial adapter and system
MX2012014180A (en) 2010-06-07 2013-05-06 Amgen Inc Drug delivery device.
CN105440134A (en) 2010-08-16 2016-03-30 安姆根公司 Antibody of combination of muscle amicine, compound and method
CA2831100A1 (en) 2011-03-31 2012-10-04 Mark Dominis Holt Vial adapter and system
JP6038884B2 (en) 2011-04-20 2016-12-07 アムゲン・インコーポレーテッド Automatic injection device
WO2012153337A2 (en) * 2011-05-11 2012-11-15 Technion Research & Development Foundation Ltd. Anti-microbial peptides and uses of same
CN106943645A (en) 2011-10-14 2017-07-14 安姆根有限公司 Injector and method of assembly
ES2693508T3 (en) 2011-10-26 2018-12-12 Amgen Inc. Methods to reduce or eliminate protein modification and degradation due to exposure to UV light
FR2982860B1 (en) 2011-11-18 2015-07-10 Ass Fr Contre Les Myopathies Use of fibromodulin and lumican to increase muscle mass
US8809259B2 (en) 2012-03-26 2014-08-19 Pronutria, Inc. Charged nutritive proteins and methods
WO2013148328A1 (en) 2012-03-26 2013-10-03 Pronutria, Inc. Nutritive proteins and methods
SG10201604458VA (en) 2012-03-26 2016-07-28 Axcella Health Inc Nutritive fragments, proteins and methods
EP2831102A4 (en) 2012-03-26 2015-12-02 Pronutria Inc Nutritive fragments, proteins and methods
AU2013204740C1 (en) 2012-05-10 2015-10-01 Agriculture Victoria Services Pty Ltd Methods of treating cancer using angiogenin or an angiogenin agonist
WO2014039189A1 (en) 2012-08-01 2014-03-13 Mcnally Elizabeth Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
EP2922590A1 (en) 2012-11-21 2015-09-30 Amgen Inc. Drug delivery device
WO2014119753A1 (en) * 2013-01-31 2014-08-07 学校法人 東京薬科大学 Myostatin-inhibiting peptide
WO2014149357A1 (en) 2013-03-22 2014-09-25 Amgen Inc. Injector and method of assembly
KR101523065B1 (en) * 2013-06-19 2015-05-27 한국기초과학지원연구원 A method for preparing size-controlled gold nanoparticles and colorimetric detection of strong acid using them
TW201601741A (en) * 2013-09-09 2016-01-16 Pinta Biotherapeutics Inc Myostatin antagonist for treatment of PEW in ESRD patients
MX2016005315A (en) 2013-10-24 2016-08-11 Amgen Inc Drug delivery system with temperature-sensitive control.
SG11201602876WA (en) 2013-10-24 2016-05-30 Amgen Inc Injector and method of assembly
US20180193623A1 (en) 2014-02-05 2018-07-12 Amgen Inc. Drug delivery system with electromagnetic field generator
JP2017518791A (en) 2014-05-07 2017-07-13 アムジエン・インコーポレーテツド Injector having a shock absorbing element
WO2015187805A2 (en) 2014-06-03 2015-12-10 Amgen Inc. Systems and methods for supporting patient use of a drug delivery device
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
AU2015332557A1 (en) 2014-10-14 2017-03-02 Amgen Inc. Drug injection device with visual and audio indicators
WO2016100055A1 (en) 2014-12-19 2016-06-23 Amgen Inc. Drug delivery device with live button or user interface field
JP2017538511A (en) 2014-12-19 2017-12-28 アムジエン・インコーポレーテツド Proximity sensor with a drug delivery device
AU2016252887A1 (en) * 2015-04-23 2017-10-26 Baker Heart and Diabetes Institute Smad7 gene delivery as a therapeutic
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
WO2017100501A1 (en) 2015-12-09 2017-06-15 Amgen Inc. Auto-injector with signaling cap
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
US20190050375A1 (en) 2016-03-15 2019-02-14 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
RU2613420C1 (en) * 2016-04-13 2017-03-16 Сергей Михайлович Юдин RECOMBINANT PROTEIN Mio-HSP, METHOD OF ITS PRODUCTION, INJECTION PREPARATION FOR MUSCLE MASS INCREASE IN FARM ANIMALS, BIRDS AND ANIMALS OF CANIDS, AS WELL AS METHOD OF USING PREPARATION
US20190192766A1 (en) 2016-04-29 2019-06-27 Amgen Inc. Drug Delivery Device with Messaging Label
US20190151544A1 (en) 2016-05-02 2019-05-23 Amgen Inc. Syringe adapter and guide for filling an on-body injector
MX2018013616A (en) 2016-05-13 2019-02-21 Amgen Inc Vial sleeve assembly.
EP3458988A1 (en) 2016-05-16 2019-03-27 Amgen Inc. Data encryption in medical devices with limited computational capability
EP3465124A1 (en) 2016-06-03 2019-04-10 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
US20190167908A1 (en) 2016-07-01 2019-06-06 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US10150115B2 (en) * 2016-07-21 2018-12-11 Spacepharma SA System and method for rehydrating powder and delivering the rehydrated powder to a reactor
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
WO2018081234A1 (en) 2016-10-25 2018-05-03 Amgen Inc. On-body injector
WO2018136398A1 (en) 2017-01-17 2018-07-26 Amgen Inc. Injection devices and related methods of use and assembly
WO2018151890A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
WO2018152073A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Insertion mechanism for drug delivery device
WO2018165143A1 (en) 2017-03-06 2018-09-13 Amgen Inc. Drug delivery device with activation prevention feature
WO2018164829A1 (en) 2017-03-07 2018-09-13 Amgen Inc. Needle insertion by overpressure
WO2018165499A1 (en) 2017-03-09 2018-09-13 Amgen Inc. Insertion mechanism for drug delivery device
WO2018183039A1 (en) 2017-03-28 2018-10-04 Amgen Inc. Plunger rod and syringe assembly system and method
WO2018226515A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
WO2018226565A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Torque driven drug delivery device
WO2018236619A1 (en) 2017-06-22 2018-12-27 Amgen Inc. Device activation impact/shock reduction
WO2018237225A1 (en) 2017-06-23 2018-12-27 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
WO2019014014A1 (en) 2017-07-14 2019-01-17 Amgen Inc. Needle insertion-retraction system having dual torsion spring system
WO2019032482A2 (en) 2017-08-09 2019-02-14 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
US20190060562A1 (en) 2017-08-22 2019-02-28 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019070472A1 (en) 2017-10-04 2019-04-11 Amgen Inc. Flow adapter for drug delivery device
WO2019070552A1 (en) 2017-10-06 2019-04-11 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
WO2019074579A1 (en) 2017-10-09 2019-04-18 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
WO2019090086A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Systems and approaches for sterilizing a drug delivery device
WO2019090303A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Fill-finish assemblies and related methods
WO2019089178A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Drug delivery device with placement and flow sensing
WO2019094138A1 (en) 2017-11-10 2019-05-16 Amgen Inc. Plungers for drug delivery devices
WO2019099324A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Door latch mechanism for drug delivery device
WO2019099322A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Autoinjector with stall and end point detection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284882B1 (en) * 1999-06-10 2001-09-04 Abbott Laboratories Myostatin gene promoter and inhibition of activation thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750375A (en) 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
JPH07502493A (en) 1991-10-08 1995-03-16
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US6465239B1 (en) 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
DE69432815T2 (en) 1993-03-19 2003-12-11 Univ Johns Hopkins Med Growth factor-8
EP1027608B1 (en) * 1998-07-30 2010-01-20 Odyssey Thera, Inc. Protein fragment complementation assays
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
CA2296434C (en) 1997-07-14 2013-10-15 University Of Liege Mutations in the myostatin gene cause double-muscling in mammals
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
GB2333706A (en) 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals
US6369201B1 (en) * 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
CA2331410C (en) 1998-05-06 2009-07-14 Metamorphix, Inc. Methods for treating diabetes by inhibiting gdf-8
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
BR0008188A (en) * 1999-01-21 2002-02-13 Metamorphix Inc growth differentiation factor inhibitors and uses therefor
IL146845D0 (en) * 1999-07-20 2002-07-25 Pharmexa As Method for down-regulating gdf-8 activity
EP1593689A3 (en) 2000-01-18 2006-04-05 Ovita Limited Myostatin and mimetics thereof
AU3930900A (en) * 2000-03-29 2001-10-08 Dgi Biotechnologies Llc Insulin and igf-1 receptor agonists and antagonists
CA2432474C (en) * 2000-12-23 2012-06-26 Dyax Corp. Fibrin binding polypeptides useful inter alia in medical imaging processes
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
AU2003301195B2 (en) 2002-12-20 2010-01-07 Amgen Inc. Binding agents which inhibit myostatin
CN1829532A (en) 2003-06-02 2006-09-06 惠氏公司 Use of myostatin (GDF8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
JP2007507429A (en) 2003-10-06 2007-03-29 モナシュ ユニバーシティー Method of treatment
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
AT540980T (en) 2003-11-13 2012-01-15 Hanmi Holdings Co Ltd Protein complex with immunoglobulin fragment and process for its manufacture
US7456149B2 (en) 2004-03-02 2008-11-25 Acceleron Pharma, Inc. ALK7 and myostatin inhibitors and uses thereof
KR20060133049A (en) 2004-03-23 2006-12-22 일라이 릴리 앤드 캄파니 Anti-myostatin antibodies
BRPI0516011A (en) * 2004-09-24 2008-08-19 Amgen Inc modified molecules fc
KR100754667B1 (en) 2005-04-08 2007-09-03 한미약품 주식회사 Immunoglobulin Fc fragment modified by non-peptide polymer and pharmaceutical composition comprising the same
PT2407486T (en) 2005-08-19 2018-02-21 Univ Pennsylvania Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders
KR101128548B1 (en) 2005-10-12 2012-03-23 일라이 릴리 앤드 캄파니 Anti-myostatin antibodies
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284882B1 (en) * 1999-06-10 2001-09-04 Abbott Laboratories Myostatin gene promoter and inhibition of activation thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP1581649A2 *
THIES S. ET AL.: 'GDF-8 propeptide binds to GDF-8 and antagonizes biological activity by inhibiting GDF-8 receptor binding' GROWTH FACTORS vol. 18, no. 4, 2001, pages 251 - 259, XP008013942 *

Also Published As

Publication number Publication date
EA200501000A3 (en) 2007-04-27
KR20160045936A (en) 2016-04-27
KR20150013350A (en) 2015-02-04
AR042545A1 (en) 2005-06-22
EP1581649B1 (en) 2011-01-26
KR20150107899A (en) 2015-09-23
AU2003301195A1 (en) 2004-07-22
CN101287484A (en) 2008-10-15
IL205265A (en) 2017-01-31
US8071538B2 (en) 2011-12-06
CA2510893A1 (en) 2004-07-15
US7803923B2 (en) 2010-09-28
JP2006524034A (en) 2006-10-26
KR101304718B1 (en) 2013-09-05
KR20120037517A (en) 2012-04-19
KR20130036378A (en) 2013-04-11
KR20110086881A (en) 2011-08-01
US7511012B2 (en) 2009-03-31
HK1084419A1 (en) 2011-08-12
EP1581649A4 (en) 2008-10-08
NO20053545D0 (en) 2005-07-19
NO335982B1 (en) 2015-04-13
BR0317538A (en) 2005-11-29
US20090220491A1 (en) 2009-09-03
JP2010193888A (en) 2010-09-09
US20100330072A1 (en) 2010-12-30
AU2003301195B2 (en) 2010-01-07
EA200501000A2 (en) 2006-06-30
DK1581649T3 (en) 2011-05-02
KR20120060250A (en) 2012-06-11
EP1581649A2 (en) 2005-10-05
RS52815B (en) 2013-10-31
NZ541253A (en) 2010-03-26
NO20141479L (en) 2005-09-08
US20130230515A1 (en) 2013-09-05
EP2272864A2 (en) 2011-01-12
IL205266D0 (en) 2011-07-31
JP2013048622A (en) 2013-03-14
KR20050091015A (en) 2005-09-14
AT496938T (en) 2011-02-15
CN101287484B (en) 2012-10-10
MXPA05006521A (en) 2005-08-26
IL205265D0 (en) 2011-07-31
PL383616A1 (en) 2008-04-14
AU2010201389A1 (en) 2010-04-29
CA2510893C (en) 2012-07-10
MEP57508A (en) 2011-05-10
EP2272864A3 (en) 2011-02-16
PT1581649E (en) 2011-04-13
KR20140004805A (en) 2014-01-13
US20090227517A1 (en) 2009-09-10
SI1581649T1 (en) 2011-09-30
CY1111388T1 (en) 2015-08-05
WO2004058988A2 (en) 2004-07-15
ZA200505481B (en) 2008-01-30
JP4959137B2 (en) 2012-06-20
EA009056B1 (en) 2007-10-26
US20040181033A1 (en) 2004-09-16
US20150175687A1 (en) 2015-06-25
TW200505474A (en) 2005-02-16
NO20053545L (en) 2005-09-08
CA2774928A1 (en) 2004-07-15
TWI328456B (en) 2010-08-11
US7928075B2 (en) 2011-04-19
ES2359562T3 (en) 2011-05-24
DE60335915D1 (en) 2011-03-10
US20120083442A1 (en) 2012-04-05
IL169168D0 (en) 2007-07-04
RS20050530A (en) 2007-09-21
CN102382172A (en) 2012-03-21
US8920798B2 (en) 2014-12-30
AR097588A2 (en) 2016-03-23

Similar Documents

Publication Publication Date Title
RU2404806C2 (en) Extension of time to progression of disease or lifetime of oncologic patients with application of her dimerisation inhibitors
RU2484097C2 (en) Method for treatment of diseases related to masp-2-dependent activation of complement (versions)
RU2416611C2 (en) Bicyclic amides as kinase inhibitors
CN1279055C (en) Antibody that immunospecifically bind to BLYS
UA77788C2 (en) 5ht2c receptor modulators, pharmaceutical composition, and use thereof
EP2220937A3 (en) Synergistic fungicidal combinations
AT546463T (en) Modified human growth hormone polypeptides and their uses
BRPI0619446A2 (en) lactam compounds, compositions and their method of modulating activity 11bHSD1
WO2004017941A3 (en) Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
AT418346T (en) Compositions for the treatment of neuropathic and neurodegenerative diseases
WO2001087977A3 (en) Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
DE602004030535D1 (en) A method of treating pain by administering a nerve growth factor antagonist and an NSAID and this composition containing
DE602004028678D1 (en) Compositions for the treatment of gastro-intestinal disorders
WO2005091944A3 (en) Glycol linked fgf-21 compounds
WO2003057698A3 (en) Spiroazacyclic compounds as monoamine receptor modulators
IL172835A (en) Composition for stabilizing active protein ingredients in pharmaceutical composition containing at least 2 amino acids
WO2004045553A3 (en) Ca125 gene and its use for diagnostic and therapeutic interventions
AT434625T (en) A process for the treatment of pain by administration of an antagonistic antibody against nerve growth factor and an opioid analgesic, and compositions containing them
AT535212T (en) The implantable drug delivery device, and for improved visibility
HRP20110368T1 (en) Biological active proteins having increased in vivo and/or vitro stability
EP2388276A3 (en) Human anti-B7RP1 neutralizing antibodies
WO2004019878A3 (en) Adzymes and uses thereof
NO341339B1 (en) Substituted gamma lactam, compositions comprising such and to the use thereof in medical treatment
EA200000331A1 (en) Pharmaceutical compositions containing plasma protein
BR0116206A (en) Peptide YY and Peptide YY agonists for the treatment of metabolic disorders

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-2005/0530

Country of ref document: YU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 169168

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/006521

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1-2005-501175

Country of ref document: PH

Ref document number: 2510893

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 383616

Country of ref document: PL

Ref document number: 1020057011611

Country of ref document: KR

Ref document number: 2004563875

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003301195

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003814258

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200505481

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 541253

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 200501000

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 20038A99052

Country of ref document: CN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 1020057011611

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003814258

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: PI0317538

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 198958

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 205266

Country of ref document: IL

Ref document number: 205265

Country of ref document: IL